Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis.
Adverse reactions
COVID-19
Hemodialysis
Vaccination
Journal
Renal replacement therapy
ISSN: 2059-1381
Titre abrégé: Ren Replace Ther
Pays: England
ID NLM: 101698599
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
05
2022
accepted:
02
08
2022
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
25
8
2022
Statut:
ppublish
Résumé
Dialysis patients are predisposed to severe disease and have a high mortality rate in coronavirus disease 2019 (COVID-19) due to their comorbidities and immunocompromised conditions. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to examine how long the effects of the vaccine are maintained and what factors affect antibody titers. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (Control group), receiving two doses of BNT162b2 vaccine, were recruited through the Japanese Society for Dialysis Therapy (JSDT) Web site in July 2021. Anti-SARS-CoV-2 immunoglobulin (IgG) (SARS-CoV-2 IgG titers) was measured before vaccination, 3 weeks after the first vaccination, 2 weeks after the second vaccination, and 3 months after the second vaccination, and was compared between Control group and HD group. Factors affecting SARS-CoV-2 IgG titers were also examined using multivariable regression analysis and stepwise regression analysis (least AIC). In addition, we compared adverse reactions in Control and HD groups and examined the relationship between adverse reactions and SARS-CoV-2 IgG titers. Our study enrolled 123 participants in the Control group (62.6% men, median age 67.0 years) and 206 patients in the HD group (64.1% men, median age 66.4 years). HD group had significantly lower SARS-CoV-2 IgG titers at 3 weeks after the first vaccination ( HD patients had significantly lower antibody titers than age- and sex-matched non-dialysis individuals over 3 months after vaccination. Dialysis time was identified as a factor affecting SARS-CoV-2 IgG titers in HD group, with longer dialysis time resulting in higher maximum SARS-CoV-2 IgG titers.
Sections du résumé
Background
UNASSIGNED
Dialysis patients are predisposed to severe disease and have a high mortality rate in coronavirus disease 2019 (COVID-19) due to their comorbidities and immunocompromised conditions. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to examine how long the effects of the vaccine are maintained and what factors affect antibody titers.
Methods
UNASSIGNED
Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (Control group), receiving two doses of BNT162b2 vaccine, were recruited through the Japanese Society for Dialysis Therapy (JSDT) Web site in July 2021. Anti-SARS-CoV-2 immunoglobulin (IgG) (SARS-CoV-2 IgG titers) was measured before vaccination, 3 weeks after the first vaccination, 2 weeks after the second vaccination, and 3 months after the second vaccination, and was compared between Control group and HD group. Factors affecting SARS-CoV-2 IgG titers were also examined using multivariable regression analysis and stepwise regression analysis (least AIC). In addition, we compared adverse reactions in Control and HD groups and examined the relationship between adverse reactions and SARS-CoV-2 IgG titers.
Results
UNASSIGNED
Our study enrolled 123 participants in the Control group (62.6% men, median age 67.0 years) and 206 patients in the HD group (64.1% men, median age 66.4 years). HD group had significantly lower SARS-CoV-2 IgG titers at 3 weeks after the first vaccination (
Conclusion
UNASSIGNED
HD patients had significantly lower antibody titers than age- and sex-matched non-dialysis individuals over 3 months after vaccination. Dialysis time was identified as a factor affecting SARS-CoV-2 IgG titers in HD group, with longer dialysis time resulting in higher maximum SARS-CoV-2 IgG titers.
Identifiants
pubmed: 35999867
doi: 10.1186/s41100-022-00427-2
pii: 427
pmc: PMC9388964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Am Soc Nephrol. 2021 Feb;32(2):385-396
pubmed: 33154174
Ren Replace Ther. 2022;8(1):8
pubmed: 35308296
J Am Soc Nephrol. 2021 Nov;32(11):2735-2742
pubmed: 34348908
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Kidney Int. 2021 Dec;100(6):1334-1335
pubmed: 34656642
Kidney Int. 2021 Jun;99(6):1490-1492
pubmed: 33887317
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5
pubmed: 34375755
Clin J Am Soc Nephrol. 2021 Jul;16(7):1073-1082
pubmed: 34031181
Vaccines (Basel). 2021 Apr 08;9(4):
pubmed: 33918085
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
JAMA. 2021 Mar 16;325(11):1101-1102
pubmed: 33576785
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
CMAJ. 2021 May 31;193(22):E793-E800
pubmed: 33980499
Front Immunol. 2021 Jun 16;12:704773
pubmed: 34220867
Nephrol Dial Transplant. 2021 Apr 11;:
pubmed: 33839785
Vaccines (Basel). 2021 Oct 04;9(10):
pubmed: 34696238
Medicina (Kaunas). 2021 Jul 19;57(7):
pubmed: 34357013
Vaccines (Basel). 2021 Jun 22;9(7):
pubmed: 34206312
Vaccine. 2022 Mar 18;40(13):1924-1927
pubmed: 35183384
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609